79 related articles for article (PubMed ID: 24398383)
1. 7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.
Cincinelli R; Musso L; Merlini L; Giannini G; Vesci L; Milazzo FM; Carenini N; Perego P; Penco S; Artali R; Zunino F; Pisano C; Dallavalle S
Bioorg Med Chem; 2014 Feb; 22(3):1089-103. PubMed ID: 24398383
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Yao H; Ji M; Zhu Z; Zhou J; Cao R; Chen X; Xu B
Bioorg Med Chem; 2015 Feb; 23(4):681-93. PubMed ID: 25614115
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
Scarpelli R; Boueres JK; Cerretani M; Ferrigno F; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
Bioorg Med Chem Lett; 2010 Jan; 20(2):488-92. PubMed ID: 20007017
[TBL] [Abstract][Full Text] [Related]
7. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
8. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
9. Novel tricyclic poly (ADP-ribose) polymerase-1/2 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis and biological evaluation.
Li H; Hu Y; Wang X; He G; Xu Y; Zhu Q
Bioorg Med Chem; 2016 Oct; 24(19):4731-4740. PubMed ID: 27561983
[TBL] [Abstract][Full Text] [Related]
10. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
Canan Koch SS; Thoresen LH; Tikhe JG; Maegley KA; Almassy RJ; Li J; Yu XH; Zook SE; Kumpf RA; Zhang C; Boritzki TJ; Mansour RN; Zhang KE; Ekker A; Calabrese CR; Curtin NJ; Kyle S; Thomas HD; Wang LZ; Calvert AH; Golding BT; Griffin RJ; Newell DR; Webber SE; Hostomsky Z
J Med Chem; 2002 Nov; 45(23):4961-74. PubMed ID: 12408707
[TBL] [Abstract][Full Text] [Related]
11. [Synthesis and activity evaluation of PARP-1 inhibitors with azaindole skeleton].
Zhou J; Zhu ZX; Chen XG; Xu BL
Yao Xue Xue Bao; 2013 Dec; 48(12):1792-9. PubMed ID: 24689236
[TBL] [Abstract][Full Text] [Related]
12. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Liu X; Shi Y; Maag DX; Palma JP; Patterson MJ; Ellis PA; Surber BW; Ready DB; Soni NB; Ladror US; Xu AJ; Iyer R; Harlan JE; Solomon LR; Donawho CK; Penning TD; Johnson EF; Shoemaker AR
Clin Cancer Res; 2012 Jan; 18(2):510-23. PubMed ID: 22128301
[TBL] [Abstract][Full Text] [Related]
13. Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Zhu GD; Gong J; Gandhi VB; Liu X; Shi Y; Johnson EF; Donawho CK; Ellis PA; Bouska JJ; Osterling DJ; Olson AM; Park C; Luo Y; Shoemaker A; Giranda VL; Penning TD
Bioorg Med Chem; 2012 Aug; 20(15):4635-45. PubMed ID: 22766219
[TBL] [Abstract][Full Text] [Related]
14. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
Wang Z; Qian H; Yiu SM; Sun J; Zhu G
J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
[TBL] [Abstract][Full Text] [Related]
15. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
[TBL] [Abstract][Full Text] [Related]
16. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Skalitzky DJ; Marakovits JT; Maegley KA; Ekker A; Yu XH; Hostomsky Z; Webber SE; Eastman BW; Almassy R; Li J; Curtin NJ; Newell DR; Calvert AH; Griffin RJ; Golding BT
J Med Chem; 2003 Jan; 46(2):210-3. PubMed ID: 12519059
[TBL] [Abstract][Full Text] [Related]
17. Development of PARP inhibitors: an unfinished story.
Patel A; Kaufmann SH
Oncology (Williston Park); 2010 Jan; 24(1):66, 68. PubMed ID: 20187324
[No Abstract] [Full Text] [Related]
18. Novel PARP-1 inhibitors based on a 2-propanoyl-3H-quinazolin-4-one scaffold.
Giannini G; Battistuzzi G; Vesci L; Milazzo FM; De Paolis F; Barbarino M; Guglielmi MB; Carollo V; Gallo G; Artali R; Dallavalle S
Bioorg Med Chem Lett; 2014 Jan; 24(2):462-6. PubMed ID: 24388690
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
[TBL] [Abstract][Full Text] [Related]
20. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Jaspers JE; Sol W; Kersbergen A; Schlicker A; Guyader C; Xu G; Wessels L; Borst P; Jonkers J; Rottenberg S
Cancer Res; 2015 Feb; 75(4):732-41. PubMed ID: 25511378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
